We are live on ! Find out more
NAVB

Navidea Biopharmaceuticals Inc.
NAVB

Delisted

NAVB was delisted on the 5th of October, 2023.

Back to rankings

49 hedge funds and large institutions have $1.43M invested in Navidea Biopharmaceuticals Inc. in 2019 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

41% more capital invested

Capital invested by funds: $1.02M → $1.43M (+$414K)

13% less funds holding

Funds holding: 56 → 49 (-7)

58% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 12

Holders
49
Holders Change
-7
Holders Change %
-12.5%
% of All Funds
1.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
10
Reduced
4
Closed
12
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
+$1K

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$39.2K
2
PFO
Pathstone Family Office
New Jersey
+$22.2K
3
Citadel Advisors
Citadel Advisors
Florida
+$18.1K
4
WS
Wedbush Securities
California
+$15.5K
5
VF
Virtu Financial
New York
+$13.4K

Top Sellers

Rank Fund Capital Flow
1
TSS
Two Sigma Securities
New York
-$7K
2
Jane Street
Jane Street
New York
-$5K
3
SWA
Stratos Wealth Advisors
Ohio
-$5K
4
CAG
Csenge Advisory Group
Florida
-$4K
5
HighTower Advisors
HighTower Advisors
Illinois
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
USAA
26
United Services Automobile Association
Texas
$4K – – –
Bank of America
27
Bank of America
North Carolina
$3K -$3.17K -1,075 -46%
JCM
28
Jacobi Capital Management
Pennsylvania
$3K – – –
HC
29
Hamilton Capital
Ohio
$2K – – –
LA
30
Lynch & Associates
Indiana
$2K – – –
MCG
31
McCollum Christoferson Group
New York
$2K – – –
MAFM
32
Mid Atlantic Financial Management
Pennsylvania
$2K – – –
RJA
33
Raymond James & Associates
Florida
$2K – – –
SIS
34
Sound Income Strategies
Florida
$2K – – –
MWPCG
35
Measured Wealth Private Client Group
New Hampshire
$2K +$147 +50 +8%
BO
36
BRR OpCo
Ohio
$2K +$590 +200 +31%
SRC
37
Sage Rhino Capital
California
$2K +$2.06K +700 New
ASN
38
Advisory Services Network
Georgia
$1K – – –
B
39
Bailard
California
$1K – – –
CIBC World Market
40
CIBC World Market
Ontario, Canada
$1K – – –
TW
41
TrinityPoint Wealth
Connecticut
$1K – – –
KFS
42
Kelly Financial Services
Massachusetts
$138 +$147 +50 New
TSS
43
Two Sigma Securities
New York
– -$7K -3,190 Closed
SWA
44
Stratos Wealth Advisors
Ohio
– -$5K -2,504 Closed
Jane Street
45
Jane Street
New York
– -$5K -2,385 Closed
HighTower Advisors
46
HighTower Advisors
Illinois
– -$4K -2,322 Closed
SWP
47
Stratos Wealth Partners
Ohio
– -$4K -2,059 Closed
CAG
48
Csenge Advisory Group
Florida
– -$4K -2,000 Closed
Invesco
49
Invesco
Georgia
– -$4K -1,763 Closed
Millennium Management
50
Millennium Management
New York
– -$2K -981 Closed
1
2
3

NAVB Hedge Fund Activity: Q1 2019 in Review

49 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2019, worth a combined $1.43M — up 41% from $1.02M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of NAVB and 5 opened new positions — a net loss of 7 holders — while 4 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $39.2K. The largest seller was Two Sigma Securities, exiting entirely with an estimated $7K sold.

  • 49 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2019, down from 56 in Q4 2018.
  • Funds reported $1.43M of Navidea Biopharmaceuticals Inc. stock for Q1 2019, up 41% quarter-over-quarter.
  • 5 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2019 and 12 closed out, a net change of -7 holders.
  • The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2019 was Vanguard Group, an estimated $39.2K added.
  • The largest Navidea Biopharmaceuticals Inc. seller in Q1 2019 was Two Sigma Securities, an estimated $7K sold.

Based on aggregated 13F filings for Q1 2019.